Given that the OS is longer in patients with clonally restricted BCR repertoires, future tumor tissue-based translational studies in SKCM should include contextual assessment of BCR repertoire features and prognostically significant B cell subsets (memory, regulatory, IL-10 producing). The gene discussed is BCR; the disease is neoplasm.